DeutschNewstral
Article
bizjournals.com on 2021-01-29 20:02
Analysts see new hope for approval of Biogen’s Alzheimer’s drug
Related news
- BBiogen’s Alzheimer’s Drug Inches Closer to Approval. That Doesn’t Make the Stock a Buy.barrons.com
- MBiogen’s controversial Alzheimer’s drug generates $2 million gross sales in first few weeks after approvalmvtelegraph.com
FDA approves Biogen’s controversial Alzheimer’s drugNew York Post- FBiogen’s Alzheimer’s drug shows early promiseft.com
Report
Biogen’s Alzheimer’s drug shows early promiseReuters- MThird member of the celebrated FDA panel resigns as a result of approval of Biogen’s Alzheimer’s drugmvtelegraph.com
- BBiogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Saysbarrons.com
- Biogen’s controversial Alzheimer’s drug made $1.6M in revenue in JuneNew York Post
- BBiogen’s Alzheimer’s Drug Has Another Shot at Success3 min readbarrons.com
Biogen’s $56 000 Alzheimer’s drug evades Biden’s cost curbspressherald.com- Biogen’s Alzheimer’s drug isn't FDA-approved yet, but it may already have a namebizjournals.com
- BBiogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.barrons.com
- MBiogen’s FDA-approved Alzheimer’s drug, first new remedy in almost twenty yearsmvtelegraph.com
- BSigns Point to FDA Approval for Biogen’s Alzheimer’s Drugbarrons.com
- BThe FDA Delayed Its Decision on Biogen’s Alzheimer’s Drug. The Stock Is Up 10%.barrons.com
- FBiogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costsft.com